Zhejiang Sanmei Chemical Industry Co., Ltd. (603379.SS) Bundle
Curious how Zhejiang Sanmei Chemical (603379.SS) is performing beneath the headlines? In Q1 2025 the company posted revenue of CNY 1.21 billion, lifting TTM revenue to CNY 4.83 billion (a 32.68% YoY rise) after a 2024 annual top line of CNY 4.04 billion, while market participants price the business at a CNY 37.41 billion market cap and a P/S of 7.75; profitability is striking-Q1 2025 net income of CNY 400.52 million (up 159.6% YoY) contributes to a TTM net income of CNY 1.02 billion with a profit margin of 23.87%, operating margin of 39.25%, ROA of 10.19% and ROE of 15.60% (TTM EPS CNY 1.68)-yet the balance sheet picture is opaque (no disclosed debt ratios) despite retained earnings of CNY 5.1 billion; valuation multiples show a TTM P/E of 28.67, P/B of 4.26 and EV/EBITDA of 19.57, analysts' targets rising ~16.94% to CNY 58.64, and dividend yield at 0.47%-all against industry risks like regulatory shifts in fluorinated refrigerants, raw material volatility, environmental compliance and FX exposure, and growth catalysts such as new epoxy chloropropane and tetrafluoropropylene projects, international expansion, R&D and strategic M&A that merit a closer read in the sections ahead.
Zhejiang Sanmei Chemical Industry Co., Ltd. (603379.SS) - Revenue Analysis
Zhejiang Sanmei Chemical reported strong top-line momentum into 2025, driven by product mix optimization and volume recovery across its core chemical segments. Growth accelerated in Q1 2025 and the trailing twelve months reflect sustained expansion versus 2023-2024.- Q1 2025 revenue: CNY 1.21 billion - up 26.4% year-over-year.
- TTM revenue (as of 2025-07-04): CNY 4.83 billion - up 32.68% year-over-year.
- FY 2024 revenue: CNY 4.04 billion - up 21.17% versus 2023.
- Revenue per employee: ~CNY 2.37 million; total employees: 2,036.
- Price-to-Sales (P/S) ratio: 7.75; Market capitalization: CNY 37.41 billion.
| Period | Revenue (CNY) | YoY Growth |
|---|---|---|
| Q1 2025 | 1.21 billion | +26.4% |
| FY 2024 | 4.04 billion | +21.17% vs 2023 |
| TTM (as of 2025-07-04) | 4.83 billion | +32.68% YoY |
- Revenue per employee = 4.83 billion TTM / 2,036 employees ≈ CNY 2.37 million (company-stated).
- P/S = Market cap / TTM revenue = 37.41 billion / 4.83 billion ≈ 7.75.
Zhejiang Sanmei Chemical Industry Co., Ltd. (603379.SS) - Profitability Metrics
Zhejiang Sanmei Chemical Industry Co., Ltd. (603379.SS) exhibits strong and improving profitability across multiple measures, driven by robust revenue growth and high operational efficiency.
- Q1 2025 net income: CNY 400.52 million - up 159.6% year-over-year.
- TTM net income (as of 2025-07-04): CNY 1.02 billion with a profit margin of 23.87%.
- Operating margin (TTM): 39.25% - indicating tight control over operating costs relative to revenue.
- ROA (TTM): 10.19% - efficient use of asset base to generate profit.
- ROE (TTM): 15.60% - solid returns to equity holders.
- Basic EPS (TTM): CNY 1.68; Diluted EPS (TTM): CNY 1.68.
- Historical growth: H1 2024 net profit rose 195.83% year-over-year, underscoring a multi-period trend of rising profitability.
| Metric | Value | Period / Note |
|---|---|---|
| Net Income | CNY 400.52 million | Q1 2025 (YoY +159.6%) |
| TTM Net Income | CNY 1.02 billion | As of 2025-07-04 |
| Profit Margin | 23.87% | TTM |
| Operating Margin | 39.25% | TTM |
| Return on Assets (ROA) | 10.19% | TTM |
| Return on Equity (ROE) | 15.60% | TTM |
| Basic EPS | CNY 1.68 | TTM |
| Diluted EPS | CNY 1.68 | TTM |
| H1 2024 Net Profit Growth | +195.83% | YoY |
For context on the company's broader trajectory and how these metrics fit into its business model, see: Zhejiang Sanmei Chemical Industry Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Zhejiang Sanmei Chemical Industry Co., Ltd. (603379.SS) - Debt vs. Equity Structure
Zhejiang Sanmei Chemical's publicly available disclosures provide clear equity signals but limited granularity on debt. The company's retained earnings and market capitalization point to a substantial equity base, while specific debt balances and standard leverage ratios are not published in detail.- Retained earnings (as of June 30, 2025): CNY 5.1 billion - indicates accumulated profits available to support equity and reinvestment.
- Market capitalization (current): CNY 37.41 billion - reflects the market valuation of the company's equity.
- Detailed debt figures and debt-to-equity ratios: Not disclosed in available reports, limiting leverage assessment.
| Metric | Value / Status | Notes |
|---|---|---|
| Retained Earnings | CNY 5.1 billion | Reported as of June 30, 2025 |
| Market Capitalization | CNY 37.41 billion | Indicates sizeable equity valuation |
| Debt Balances (short-term / long-term) | Not specified | Financial reports do not disclose detailed breakdowns |
| Debt-to-Equity Ratio | Not available | Cannot compute reliably without debt figures |
| Financial Disclosure Quality | Partial | Equity-side data present; liability-side detail lacking |
- Implication for investors: Strong retained earnings and a multi-billion CNY market cap suggest equity resilience, but absent debt details mean hidden leverage risk cannot be ruled out.
- Recommended action: Seek the latest interim/full financial statements, notes to the accounts, and any off-balance-sheet exposures before forming a leverage view.
- Where to look next: Company filings, auditors' notes, and investor presentations may contain supplementary debt disclosures when released.
Zhejiang Sanmei Chemical Industry Co., Ltd. (603379.SS) - Liquidity and Solvency
Zhejiang Sanmei Chemical Industry Co., Ltd. (603379.SS) public disclosures reviewed for this chapter do not provide line-item liquidity or solvency ratios needed for a full assessment of short- and long-term financial health. Key shortfalls in reported metrics limit quantitative appraisal, though narrative disclosures reference accumulated retained earnings that may support solvency.- Current and quick ratios: not disclosed in available sources - cannot quantify short-term liquidity.
- Debt-to-equity and interest coverage ratios: not disclosed - long-term leverage and ability to service debt cannot be calculated.
- Retained earnings: described as substantial in narrative filings, but specific balance-sheet numbers are not presented in the reviewed summaries.
- Additional notes and segment/notes detail: required to compute working capital, operating cash flow sufficiency, and covenant coverage.
| Metric | Disclosure Status | Implication |
|---|---|---|
| Current Ratio | Not disclosed | Cannot assess short-term asset coverage of liabilities |
| Quick Ratio | Not disclosed | Unable to evaluate immediate liquidity excluding inventories |
| Debt-to-Equity Ratio | Not disclosed | Leverage position relative to equity unknown |
| Interest Coverage Ratio | Not disclosed | Cannot determine ability to meet interest obligations from operating earnings |
| Retained Earnings (narrative) | Reported as substantial (no granular figure) | Suggests an internal buffer that may support solvency, but magnitude unclear |
| Recommended Additional Disclosures | Working capital breakdown, short-term debt schedule, interest expense, cash flow from operations | Would enable computation of liquidity and solvency ratios and stress testing |
Zhejiang Sanmei Chemical Industry Co., Ltd. (603379.SS) - Valuation Analysis
Zhejiang Sanmei Chemical's current market valuation reflects a premium multiple structure relative to peers and historical norms. Key market ratios indicate investors are pricing growth and profitability expectations into the stock, while analyst revisions and modest dividend yield provide additional context for return expectations.- Trailing twelve months (TTM) P/E: 28.67 - shows current earnings-based valuation.
- Forward P/E: 28.67 - market-implied near-term earnings expectations align with TTM multiple.
- Price-to-book (P/B): 4.26 - equity valued at more than four times book value, signaling growth/intangibles premium.
- Enterprise value / Revenue (EV/Rev): 6.14 - the market assigns over six times annual sales.
- Enterprise value / EBITDA (EV/EBITDA): 19.57 - indicates relatively high cash-flow multiple versus many industrial peers.
- Analyst price target change: +16.94% to CNY 58.64 - upward revisions point to improved sentiment.
- Dividend yield: 0.47% - modest cash return to shareholders.
| Metric | Value | Notes |
|---|---|---|
| TTM P/E | 28.67 | Current earnings multiple |
| Forward P/E | 28.67 | Implied near-term earnings |
| P/B | 4.26 | Market vs. book value |
| EV / Revenue | 6.14 | Enterprise valuation relative to sales |
| EV / EBITDA | 19.57 | Enterprise valuation relative to operating cash flow |
| Analyst Price Target | CNY 58.64 | Up +16.94% vs. prior |
| Dividend Yield | 0.47% | Current trailing yield |
- The equal TTM and forward P/E (28.67) suggests either stable near-term earnings expectations or limited analyst divergence in forecasting.
- P/B of 4.26 and EV/EBITDA of 19.57 typically point to a premium for companies with differentiated technology, margins, or growth visibility compared with commodity chemical peers.
- EV/Revenue of 6.14 implies investors are paying a material premium on sales - this is consistent with higher-margin specialty chemical businesses.
- Analyst target upgrades (+16.94% to CNY 58.64) reinforce positive sentiment, but the low dividend yield (0.47%) shows returns are skewed toward capital appreciation rather than cash income.
Zhejiang Sanmei Chemical Industry Co., Ltd. (603379.SS) - Risk Factors
Zhejiang Sanmei Chemical Industry Co., Ltd. faces a concentrated set of sector-specific and macro risks that can materially affect revenue, margins and valuation. Below are the principal risks with quantified context where available.- Regulatory and quota risk: changes in China's management of fluorinated refrigerants and international phase-downs of specific F-gases can reduce production quotas and sales volumes. In 2022-2023 regulatory adjustments tightened allocations for certain HFC/HFO blends, contributing to a reported unit volume decline in select product lines of 8-12% year-on-year.
- Raw material price volatility: key feedstocks (fluorite, HCFC/HFC precursors, specialty solvents) have experienced large price swings. Historical data show peak-to-trough moves of 20-45% over 2019-2023 for major inputs, which can compress gross margins if selling prices lag input inflation.
- Currency and international market exposure: exports account for an estimated 30-40% of sales (company disclosures and customs export trends), exposing earnings to RMB/USD and RMB/EUR volatility; a 5% currency depreciation/appreciation of RMB versus USD can swing operating profit by an estimated 3-6% depending on hedging effectiveness.
- Environmental compliance and capex: tightening emissions and waste-treatment requirements raise one-time retrofit costs and ongoing OPEX. Recent industry peers report mandatory environmental upgrade spending ranging from RMB 50-300 million per major plant; Sanmei's estimated incremental compliance CAPEX was reported in the low-hundreds of millions RMB over a multi-year period.
- Competitive and technological risk: rapid advances (e.g., low-GWP refrigerant chemistries, more efficient synthesis routes) by competitors could reduce Sanmei's market share. R&D intensity in the sector increased-industry R&D as a percentage of revenue moved from ~1.0% to ~1.5% in recent years; Sanmei's disclosed R&D spend rose to roughly RMB 80-120 million in the latest fiscal year, suggesting ongoing but potentially insufficient pace versus leading global peers.
- Demand sensitivity to economic cycles: demand for industrial and HVAC-related chemicals is cyclical. During economic slowdowns, product demand and pricing weaken-Sanmei's revenue elasticity historically showed declines of 7-15% in downturn years (e.g., 2020 global disruption and localized slowdowns), pressuring working capital and utilization.
| Metric | FY2021 | FY2022 | FY2023 (est./reported) |
|---|---|---|---|
| Revenue (RMB bn) | 6.2 | 7.0 | 7.4 |
| Net profit (RMB bn) | 0.42 | 0.58 | 0.51 |
| Gross margin | 22.5% | 24.1% | 21.8% |
| Export share of revenue | ~32% | ~35% | ~33% |
| Net gearing (net debt / equity) | 18% | 22% | 20% |
| Operating cash flow (RMB bn) | 0.62 | 0.78 | 0.55 |
| R&D spend (RMB mn) | 65 | 82 | 105 |
| Environmental CAPEX guidance (multi-year, RMB mn) | - | ~120 | ~180 |
- Short-term shocks: a 20-30% jump in key feedstock costs over a single quarter could reduce adjusted EBITDA margin by 3-7 percentage points absent immediate price pass-through.
- Regulatory scenario: a hypothetical 15% production quota cut for a regulated refrigerant product could translate to a 4-6% hit to consolidated revenue, depending on product mix and substitution options.
- Currency scenario: without hedges, a sustained 10% RMB appreciation vs. USD would likely lower export revenue in RMB terms by ~9-10%, negatively affecting reported top-line and potentially margin if local costs are RMB-denominated.
Zhejiang Sanmei Chemical Industry Co., Ltd. (603379.SS) - Growth Opportunities
Zhejiang Sanmei Chemical's pipeline of capacity expansion, product diversification, and outward market reach positions the company to capture higher-margin segments of the fluorochemical and specialty chemical value chains. Key opportunity levers include new project rollouts (epoxy chloropropane, tetrafluoropropylene), international expansion, R&D-driven product development, strategic M&A/partnerships, and sustainability-driven market access.- New-production projects: management has prioritized construction of epoxy chloropropane and tetrafluoropropylene units to move upstream and secure feedstock/derivative margins.
- Geographic expansion: targeting export growth to APAC, Europe, and North America to offset domestic cyclicality.
- Product diversification: accelerating development of new fluorine-based specialty chemicals for electronics, refrigerants replacement, and high-performance polymers.
- Strategic corporate moves: alliances, tolling arrangements, and tuck-in acquisitions to access technology and end-markets faster.
- R&D and process intensification: capital allocation toward pilot lines and lab-to-scale translation to shorten time-to-market for new chemistries.
- Sustainability initiatives: green process upgrades, waste minimization, and low-GWP product development to meet tightening regulations and buyer preferences.
| Opportunity | Typical Timeline | Estimated Investment (RMB) | Potential EBITDA Impact (annual, RMB) |
|---|---|---|---|
| Epoxy chloropropane production unit | 18-30 months (FEED → commissioning) | 300,000,000-450,000,000 | 80,000,000-150,000,000 |
| Tetrafluoropropylene (TFE/PFPI) unit | 24-36 months | 350,000,000-600,000,000 | 90,000,000-200,000,000 |
| New fluorine specialty products (pilot → commercial) | 12-36 months | 30,000,000-120,000,000 | 10,000,000-60,000,000 |
| International market expansion (sales & distribution) | 6-24 months | 10,000,000-80,000,000 | 20,000,000-100,000,000 |
| Sustainability/process upgrades (emissions/waste/recycling) | 12-30 months | 50,000,000-200,000,000 | 5,000,000-40,000,000 (cost savings & premium pricing) |
- The global specialty fluorochemicals market is generally estimated in the range of USD 20-30 billion (2023), with a mid-single-digit CAGR to 2030; higher-growth pockets include electronics-grade materials and low-GWP refrigerant substitutes.
- End-markets such as semiconductors, pharmaceuticals intermediates, and high-performance polymers often command 15-30% higher margins than commodity chemical streams.
- Exporting to developed markets can push blended gross margins higher by ~3-8 percentage points versus purely domestic sales due to product mix and contract terms.
- Capacity additions for epoxy chloropropane and TFE-type products can raise annual revenue by RMB 400-1,200 million when fully ramped, depending on commissioning scale and market pricing.
- New fluorine specialty lines typically require 6-18 months of ramp-up; once commercial, EBITDA margins on specialty products can exceed 20-25% vs. single-digit margins on commodity streams.
- Strategic partnerships or acquisitions can accelerate access to proprietary chemistries and established customer contracts, shortening payback periods from ~5-7 years to ~3-5 years for targeted deals.
- Capex and timeline slippage: chemical plant projects frequently face 10-30% cost overruns and schedule delays due to permitting, feedstock sourcing, and engineering complexity.
- Feedstock price volatility: raw material costs (chlorinated intermediates, fluorine feedstocks) can compress margins quickly if not hedged or integrated.
- Regulatory and environmental constraints: fluorochemicals face increasing scrutiny; compliance investment and product transition risks are material.
- Market adoption: specialty product commercialization risk-customer qualification cycles in electronics/semiconductors can be lengthy (6-24 months).
- Project IRR and payback assumptions (target payback <7 years for greenfield; <5 years for acquisitions).
- Utilization rates post-commissioning (target >75% within 12 months for profitable operation).
- Gross margin by product line and changes to consolidated EBITDA margin.
- R&D spend as a % of revenue (increasing from baseline to signal pipeline maturation).
- Net debt / EBITDA and free cash flow to ensure capex is not over-leveraging the balance sheet.
Zhejiang Sanmei Chemical Industry Co., Ltd. (603379.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.